MARKET

ORIC

ORIC

Oric Pharmaceuticals, Inc.
NASDAQ
8.17
-0.01
-0.12%
After Hours: 8.32 +0.15 +1.84% 19:11 01/02 EST
OPEN
8.24
PREV CLOSE
8.18
HIGH
8.33
LOW
8.04
VOLUME
805.54K
TURNOVER
--
52 WEEK HIGH
14.93
52 WEEK LOW
3.895
MARKET CAP
795.67M
P/E (TTM)
-4.7198
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ORIC last week (1222-1226)?
Weekly Report · 12/29/2025 09:06
Oric Pharmaceuticals (ORIC) Receives a Buy from Evercore ISI
TipRanks · 12/23/2025 08:26
Wedbush Reaffirms Their Buy Rating on Oric Pharmaceuticals (ORIC)
TipRanks · 12/22/2025 13:36
Weekly Report: what happened at ORIC last week (1215-1219)?
Weekly Report · 12/22/2025 09:06
Wells Fargo Remains a Buy on Oric Pharmaceuticals (ORIC)
TipRanks · 12/17/2025 17:05
Oric Pharmaceuticals Currently Down Eight Consecutive Days, On Track for Longest Losing Streak Since June 2024 -- Data Talk
Dow Jones · 12/16/2025 19:41
Weekly Report: what happened at ORIC last week (1208-1212)?
Weekly Report · 12/15/2025 09:06
ORIC Pharmaceuticals (ORIC): Valuation Check After Encouraging Enozertinib Phase 1b Lung Cancer Data
Simply Wall St · 12/09/2025 09:12
More
About ORIC
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.

Webull offers ORIC Pharmaceuticals Inc stock information, including NASDAQ: ORIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORIC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORIC stock methods without spending real money on the virtual paper trading platform.